No Data
No Data
Express News | Longboard Pharmaceuticals Inc : Baird Raises Target Price to $60 From $36
Baird Adjusts Price Target on Longboard Pharmaceuticals to $60 From $36, Maintains Outperform Rating
Longboard Pharmaceuticals (LBPH) has an average buy rating and price target range of $32 to $90, according to analysts polled by Capital IQ.Price: 37.01, Change: +2.83, Percent Change: +8.28
Baird Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $60
Baird analyst Joel Beatty maintains $Longboard Pharmaceuticals(LBPH.US)$ with a buy rating, and adjusts the target price from $36 to $60.According to TipRanks data, the analyst has a success rate of 4
Longboard Pharmaceuticals Is Maintained at Outperform by Baird
Longboard Pharmaceuticals Is Maintained at Outperform by
Longboard Pharmaceuticals Price Target Raised to $60.00/Share From $36.00 by Baird
Longboard Pharmaceuticals Price Target Raised to $60.00/Share From $36.00 by
Baird Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $60
Baird analyst Joel Beatty maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $36 to $60.